Patents by Inventor Fabian Kiessling

Fabian Kiessling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133888
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars RÖSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Patent number: 10894094
    Abstract: The invention relates to the use of tetrapyrroles conjugated compounds as contrast agent in magnetic resonance imaging (MRI). In particular conjugates of natural hemin that can be embedded in gels and implants to image local delivery in MRI.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 19, 2021
    Assignee: NANO4IMAGING GMBH
    Inventors: Fabian Kiessling, Paul Borm, Jozef Cremers, Nihan Güvener
  • Publication number: 20200188372
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: June 18, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Publication number: 20200179354
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 11, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Publication number: 20200155674
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: May 21, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Patent number: 10391185
    Abstract: The invention provides a multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles having a gas core and carrying at least one photoacoustic agent in its shell that stabilizes the gas core, for use in ultrasound and photoacoustic imaging. Such multimodal ultrasound and photoacoustic contrast agent is also suitable as a carrier of drugs and for use in photodynamic therapy, and for tissue imaging ex vivo.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: August 27, 2019
    Assignees: Fujifilm VisualSonics, Inc., RWTH Aachen
    Inventors: Fabian Kiessling, Twan Lammers, Stanley Fokong Nyongamsen, Katrin Suppelt
  • Publication number: 20190209714
    Abstract: The invention relates to the use of tetrapyrroles conjugated compounds as contrast agent in magnetic resonance imaging (MRI). In particular conjugates of natural hemin that can be embedded in gels and implants to image local delivery in MRI.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 11, 2019
    Applicant: NANO4IMAGING GMBH
    Inventors: Fabian KIESSLING, Paul BORM, Jozef CREMERS, Nihan GÜVENER
  • Publication number: 20170252467
    Abstract: The invention provides a multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles having a gas core and carrying at least one photoacoustic agent in its shell that stabilizes the gas core, for use in ultrasound and photoacoustic imaging. Such multimodal ultrasound and photoacoustic contrast agent is also suitable as a carrier of drugs and for use in photodynamic therapy, and for tissue imaging ex vivo.
    Type: Application
    Filed: November 26, 2015
    Publication date: September 7, 2017
    Inventors: Fabian Kiessling, Twan Lammers, Stanley Fokong Nyongamsen, Katrin Suppelt
  • Publication number: 20170130193
    Abstract: In a first aspect, the present application relates to a method for producing a tissue model comprising supply structures. In a further aspect, the application relates to tissue models that can he obtained in this way and to the use of said tissue models as models for tissue genesis, in particular tumorigenesis, including angiogenesis, in the tissue model. Finally, a method for testing and identifying active ingredient candidates, including treatment strategies, is provided.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 11, 2017
    Inventors: Andreas BLAESER, Benjamin THEEK, Twan LAMMERS, Fabian KIESSLING, Horst FISCHER
  • Patent number: 8195275
    Abstract: A system and method of evaluating the effectiveness of antiangionetic therapy is described. A patient or test animal is treated with an antiangionetic substance. Magnetic resonance imaging data is obtained prior to and subsequent to the treatment. The parameters of the imaging process are configured so that, by administering a intravascular contrast agent, the relative size of the microvascular and the total vascular volumes in a region of interest may be obtained, so as to form a vascular size index. The value of the vascular size index and other pharmacokinetic data obtained by the administration of a diffusible contrast agent are used to assess the efficacy of the treatment or the antiangionetic substance being studied.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 5, 2012
    Assignee: Siemens Aktiengesellschaft
    Inventors: Stefan Zwick, Ralph Strecker, Fabian Kiessling, Arne Hengerer, Sebastian Schmidt
  • Publication number: 20080294035
    Abstract: A system and method of evaluating the effectiveness of antiangionetic therapy is described. A patient or test animal is treated with an antiangionetic substance. Magnetic resonance imaging data is obtained prior to and subsequent to the treatment. The parameters of the imaging process are configured so that, by administering a intravascular contrast agent, the relative size of the microvascular and the total vascular volumes in a region of interest may be obtained, so as to form a vascular size index. The value of the vascular size index and other pharmacokinetic data obtained by the administration of a diffusible contrast agent are used to assess the efficacy of the treatment or the antiangionetic substance being studied.
    Type: Application
    Filed: May 21, 2008
    Publication date: November 27, 2008
    Inventors: Stefan Zwick, Ralph Strecker, Fabian Kiessling, Arne Hengerer, Sebastian Schmidt
  • Publication number: 20080139927
    Abstract: The present invention relates to an implantable chamber (1) with a connecting element (2), comprising a connecting sleeve (6) and a surrounding contact surface (7), an insert element (3), comprising an insert sleeve (8) and a surrounding abutment surface (9). The insert sleeve (8) is inserted into the connecting sleeve (6) of the connecting element (2). The implantable chamber (1) further comprises a cap (4) with a surrounding edge (11), the cap (4) partly covering the connecting element (2) and the insert element (3), leaving an opening (13) on one side. The implantable chamber (1) contains a passive resonance circuit (14) with an inductance and a capacitance, the passive resonance circuit (14) surrounding at least part of a cavity (15) inside the insert element (3).
    Type: Application
    Filed: January 10, 2006
    Publication date: June 12, 2008
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG
    Inventors: Michael Bock, Reiner Umathum, Norbert Fusenig, Margaretha Muller, Fabian Kiessling